Sionna Therapeutics, Inc. SION
Sionna Therapeutics, Inc. (Nasdaq: SION) is a rare genetic drug developer. Its lead program, SION-719, is in Phase 2 for Cystic fibrosis.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SION-719 | Cystic fibrosis (PreciSION CF Phase 2a) | small molecule | Phase 2 |
| SION-451 + SION-109 combination | Cystic fibrosis | small molecule | Phase 1 |
Recent results and decisions
- Aug 10, 2026missed Phase 2a missed key activity endpoint: -1.0 mmol/L mean placebo-adjusted sweat chloride change (p=0.7); well tolerated; SION-719 not advancing as add-on to standard of care.
The PreciSION CF trial did not meet its key activity endpoint, with a -1.0 mmol/L mean placebo-adjusted sweat chloride change (p=0.7).
Filing - Aug 10, 2026positive Phase 1 in 120 healthy subjects met safety, tolerability and PK objectives; SION-451 + SION-2222 chosen as preferred dual combination; two discontinuations for LFT elevation/flu-like symptoms and one for rash.
The Phase 1 trial of SION-451 in dual combinations with either SION-2222 or SION-109 in healthy subjects, achieved the safety, tolerability, and pharmacokinetic (PK) objectives, including target exposures defined prior to the Phase 2a PreciSION CF results.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.